Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Stoke Therapeutics ( (STOK) ).
At the 2025 American Epilepsy Society Annual Meeting, Stoke Therapeutics and Biogen presented data supporting the potential of zorevunersen as a disease-modifying treatment for Dravet syndrome. Long-term studies demonstrated significant seizure reductions, cognitive and behavioral improvements, and enhanced quality of life for patients. The findings, including EEG analysis, suggest zorevunersen’s potential to address the underlying causes of Dravet syndrome, offering hope for improved patient outcomes.
The most recent analyst rating on (STOK) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.
Spark’s Take on STOK Stock
According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.
Stoke Therapeutics’ overall stock score reflects its improved financial performance and operational efficiency, offset by valuation concerns and technical indicators suggesting potential short-term weakness. The lack of earnings call data and corporate events limits additional insights.
To see Spark’s full report on STOK stock, click here.
More about Stoke Therapeutics
Stoke Therapeutics, Inc. is a biotechnology company focused on restoring protein expression using RNA medicine, with a particular emphasis on developing treatments for genetic diseases such as Dravet syndrome.
Average Trading Volume: 1,191,703
Technical Sentiment Signal: Buy
Current Market Cap: $1.77B
For an in-depth examination of STOK stock, go to TipRanks’ Overview page.